Free Call: 1800 792 676
Seminar Invitation: Pitfalls for SMEs in protecting and claiming incentives for new developments
Presented by:
- Joe Seisdedos (Wrays)
- Glenn Cosgrave (Bates Cosgrave)
- Adam Rogers (Swanson Reed)
Join Swanson Reed, Bates Cosgrave and Wrays for a practical workshop that will focus on the problems that every day companies face in protecting, and claiming incentives for their new products.
You will hear from three industry experts on a range of topics, including tax issues, R&D tax incentives and patent protection.
On conclusion of the presentation, participants will have an opportunity to ask the panel any specific questions in a friendly and constructive forum.
| Time | Presentation | Presenter | |
| 7:00am – 7:30am: | Session 1: Protecting Intellectual Property (IP) | Joe Seisdedos | |
| 7:30am – 8:00am: | Session 2: IP & Relevant Tax Considerations | Glenn Cosgrave | |
| 8:00am – 8:30am: | Session 3: R&D Tax Incentives | Adam Rogers | |
| 8:30am – 9:00am: | Session 4: Panel Q&A and Networking Opportunity | ||
| Joe Seisdedos | Glenn Cosgrave | Adam Rogers |
 |
 |
 |
Sydney Seminar:
Tuesday, 17th June 2014
7am – 9am
Hilton Sydney
488 George Street
Sydney, 2000
Cost: Free!
Register Before: Friday 13th June
Full attendance at this workshop will yield 2 CPE hours towards the Tax Practitioners Board’s (TPB) CPE requirements.
Contact Amy Nolan for more information:
Ph: 02 8006 9155
Mob: 0435 713 493
Are you Eligible to claim R&D? Take our R&D Eligibility Survey and find out.
Latest News
CBA Settlement of Disputed Claims for Software R&D Activities
CBA have announced to the ASX on 18 March that they have entered into a settlement in respect of a tax dispute re: the eligibility of claims for software development R&D activities. Below is an extract from the ASX announcement: Commonwealth Bank of Australia has agreed to withdraw from all current proceedings with the ATO and Innovation and Science Australia (ISA) before the AAT in respect of the eligibility of R&D claims that were made for the years ended 30 […]
Australia’s Attractiveness for Clinical Trials
To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to a disproportionate number of drugs being developed for rare diseases (affecting less than 200,000 in the US at any given time) due to a 25.3% success rate versus 3.4% for oncology. Many argue this is unsustainable and there is pressure […]
Quick Contact
News & Research
News & Research
News & ResearchCBA Settlement of Disputed Claims for Software R&D Activities
CBA have announced to the ASX on 18 March that they have entered into a settlement in respect of a tax dispute re: the eligibility of claims for software development R&D activities. Below is an extract from the ASX announcement: […]
Australia’s Attractiveness for Clinical Trials
To bring a new drug to market, an average of 12 years and $1.7 billion (US) in R&D spending is required. Yet only 1 in 5,000 drugs that begin preclinical testing make it to the market. This has led to […]
